Collegium Pharmaceutical Financials - Benzinga

Collegium Pharmaceutical Inc

COLLNASDAQ

Trade with Public

Trade with Public

$25.35

-1.09-4.12%

At close: Aug 28, 5:00 PM EST

$25.35

N/A

After Hours: 4:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Collegium Pharmaceutical Financials

Collegium Pharmaceutical (COLL) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Collegium Pharmaceutical Q2 Adj. EPS $1.92 Beats $1.72 Estimate, Sales $199.878M Miss $201.206M Estimate

Benzinga Newsdesk

PRO
Collegium Pharmaceutical Lowers FY2026 Sales Guidance from $865.000M-$895.000M to $825.000M-$855.000M vs $872.278M Est

Collegium Pharmaceutical (NASDAQ:COLL) lowers FY2026 sales outlook from $865.000 million-$895.000 million to $825.000 million-$855.000 million vs $872.278 million estimate.

Benzinga Newsdesk

PRO
Collegium Pharmaceutical Affirms FY2026 Sales Guidance of $805.000M-$825.000M vs $825.757M Est

Collegium Pharmaceutical (NASDAQ:COLL) affirms FY2026 sales outlook from $805.000 million-$825.000 million to $805.000 million-$825.000 million vs $825.757 million estimate.

Benzinga Newsdesk

PRO
Collegium Pharmaceutical Q1 Adj. EPS $1.76 Beats $1.59 Estimate, Sales $193.520M Beat $185.984M Estimate

Collegium Pharmaceutical (NASDAQ:COLL) reported quarterly earnings of $1.76 per share which beat the analyst consensus estimate of $1.59 by 10.69 percent. This is a 18.12 percent increase over earnings of $1.49 per share

Benzinga Newsdesk

PRO
Collegium Pharmaceutical Sees FY2026 Sales $805.000M-$825.000M vs $808.877M Est

Collegium Pharmaceutical (NASDAQ:COLL) sees FY2026 sales of $805.000 million-$825.000 million vs $808.877 million analyst estimate.

Benzinga Newsdesk

Insights into Collegium Pharmaceutical Q4 Earnings

Benzinga Insights